Disease Domain | Count |
---|---|
Neoplasms | 4 |
Immune System Diseases | 2 |
Nervous System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Aptamers | 1 |
Vaccine | 1 |
Mesenchymal stem cell therapy | 1 |
Target |
Mechanism μ opioid receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date07 Aug 2020 |
Target- |
Mechanism Cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. NZ |
First Approval Date25 May 2012 |
Target |
Mechanism PDI inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Oliceridine fumarate ( μ opioid receptor ) | Pain, Postoperative More | Phase 3 |
Remestemcel-L (Mesoblast) | Crohn Disease More | Phase 2 Clinical |
Breast cancer vaccine (Anixa Biosciences/Cleveland Clinic) | Breast Cancer More | Phase 1 |
CCF-642-34 ( PDI ) | Multiple Myeloma More | Preclinical |
C10.36 | Neoplasms More | Discovery |